Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression

References

• Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.
   PubMed Web of Science ®Google Scholar
• Rizeq B, Malki MI. The role of CCL21/CCR7 chemokine axis in breast cancer progression. Cancers (Basel). 2020;12(4). DOI:10.3390/cancers12041036.
   Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–127.
   PubMed Web of Science ®Google Scholar
• Zhao L, Xia J, Wang X, et al. Transcriptional regulation of CCL20 expression. Microbes Infect. 2014;16(10):864–870.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Rubie C, Aebersold DM, et al. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer. 2009;125(4):741–745.
   PubMed Web of Science ®Google Scholar
• Mukaida N, Sasaki S-I, Baba T, et al. Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm. 2014;2014:170381.
   PubMed Web of Science ®Google Scholar
• Griffith JW, Sokol CL, Luster AD, et al. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32(1):659–702.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Burkhardt AM, Homey B, et al. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597–606.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W, et al. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
   PubMed Web of Science ®Google Scholar
• Do HTT, Lee CH, Cho J, et al. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel). 2020;12(2):287.
   PubMed Web of Science ®Google Scholar
• Reyes ME, de La Fuente M, Hermoso M, et al. Role of CC chemokines subfamily in the platinum drugs resistance promotion in cancer. Front Immunol. 2020;11(901). DOI:10.3389/fimmu.2020.00901.
   Google Scholar
• Osuala KO, Sloane BF. Many roles of CCL20: emphasis on breast cancer. Postdoc J. 2014;2(3):7–16.
   PubMedGoogle Scholar
• Ranasinghe R, Eri R. Modulation of the CCR6-CCL20 axis: a potential therapeutic target in inflammation and cancer. Medicina (B Aires). 2018;54(5):88.
   Google Scholar
• Frick VO, Rubie C, Keilholz U, et al. Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: an overview. World J Gastroenterol. 2016;22(2):833–841.
   PubMed Web of Science ®Google Scholar
• Nelson RT, Boyd J, Gladue RP, et al. Genomic organization of the CC chemokine MIP-3α/CCL20/LARC/EXODUS/SCYA20, showing gene structure, splice variants, and chromosome localization. Genomics. 2001;73(1):28–37.
   PubMed Web of Science ®Google Scholar
• Scheerens H, Hessel E, De Waal-malefyt R, et al. Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-/- mice and Rag-2-/- mice reconstituted with CD4+CD45RBhigh T cells. Eur J Immunol. 2001;31(5):1465–1474.
   PubMed Web of Science ®Google Scholar
• Atreya R, Neurath MF. Chemokines in inflammatory bowel diseases. Dig Dis. 2010;28(3):386–394.
   PubMed Web of Science ®Google Scholar
• Liu B, Jia Y, Ma J, et al. Tumor-associated macrophage-derived CCL20 enhances the growth and metastasis of pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 2016;48(12):1067–1074.
   PubMed Web of Science ®Google Scholar
• Wang D, Yang L, Yu W, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-kappaB signaling. J Immunother Cancer. 2019;7(1):215.
   PubMed Web of Science ®Google Scholar
• Liu W, Wang W, Wang X, et al. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer Lett. 2020;472:59–69.
   PubMed Web of Science ®Google Scholar
• Du D, Liu Y, Qian H, et al. The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma. Int J Mol Sci. 2014;15(4):6441–6452.
   PubMed Web of Science ®Google Scholar
• Marsigliante S, Vetrugno C, Muscella A, et al. Paracrine CCL20 loop induces epithelial-mesenchymal transition in breast epithelial cells. Mol Carcinog. 2016;55(7):1175–1186.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W, et al. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Hoover DM, et al. Many chemokines including CCL20/MIP-3α display antimicrobial activity. J Leukoc Biol. 2003;74(3):448–455.
   PubMed Web of Science ®Google Scholar
• Kaser A, Ludwiczek O, Holzmann S, et al. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 2004;24(1):74–85.
   PubMed Web of Science ®Google Scholar
• Matsui T, Akahoshi T, Namai R, et al. Selective recruitment of CCR6-expressing cells by increased production of MIP-3α in rheumatoid arthritis. Clin Exp Immunol. 2001;125(1):155–161.
   PubMed Web of Science ®Google Scholar
• Furue K, Ito T, Tsuji G, et al. The CCL20 and CCR6 axis in psoriasis. Scand J Immunol. 2020;91(3):e12846.
   PubMed Web of Science ®Google Scholar
• Kadomoto S, Izumi K, Mizokami A, et al. The CCL20-CCR6 axis in cancer progression. Int J Mol Sci. 2020;21(15):5186.
   PubMed Web of Science ®Google Scholar
• Guo L, Situ HL, Wang ZY, et al. Mechanism of jinrong granule in inhibiting the invasion of breast cancer cells by the CXCL-1-CXCR2/CCL20 pathway. J Biol Regul Homeost Agents. 2020;34(3):969–976.
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29(1):235–271.
   PubMed Web of Science ®Google Scholar
• Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125–1131.
   PubMed Web of Science ®Google Scholar
• Aruga T, Suzuki E, Saji S, et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep. 2009;22(2):273–278.
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373–5380.
   PubMed Web of Science ®Google Scholar
• Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000–2009.
   PubMed Web of Science ®Google Scholar
• Li L, Yang C, Zhao Z, et al. Skewed T-helper (Th)1/2- and Th17/T regulatory‑cell balances in patients with renal cell carcinoma. Mol Med Rep. 2015;11(2):947–953.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang N, Li Q, et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PloS One. 2011;6(4):e19495.
   PubMed Web of Science ®Google Scholar
• Chen KJ, Lin SZ, Zhou L, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PloS One. 2011;6(9):e24671.
   PubMed Web of Science ®Google Scholar
• Zhao X, Li Y, Wang X, et al. Synergistic association of FOXP3+ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer: a retrospective cohort study. Medicine (Baltimore). 2019;98(50):e18403.
   PubMed Web of Science ®Google Scholar
• Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20:323–370.
   PubMed Web of Science ®Google Scholar
• Chikamatsu K, Sakakura K, Whiteside TL, et al. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck. 2007;29(2):120–127.
   PubMed Web of Science ®Google Scholar
• Xu L, Xu W, Qiu S, et al. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol. 2010;135(3):466–475.
   PubMed Web of Science ®Google Scholar
• Michea P, Noël F, Zakine E, et al. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat Immunol. 2018;19(8):885–897.
   PubMedGoogle Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296–306.
   PubMed Web of Science ®Google Scholar
• Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med. 1999;190(10):1417–1426.
   PubMed Web of Science ®Google Scholar
• Treilleux I, Blay J-Y, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004;10(22):7466–7474.
   PubMed Web of Science ®Google Scholar
• Thomachot MC, Bendriss-Vermare N, Massacrier C, et al. Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1ahighCD86−Langerin- and CD1a+CD86+Langerin+ phenotypes. Int J Cancer. 2004;110(5):710–720.
   PubMed Web of Science ®Google Scholar
• De Palma M, Biziato D, Petrova TV, et al. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457–474.
   PubMed Web of Science ®Google Scholar
• Mao Y, Wang Y, Dong L, et al. Hypoxic exosomes facilitate angiogenesis and metastasis in esophageal squamous cell carcinoma through altering the phenotype and transcriptome of endothelial cells. J Exp Clin Cancer Res. 2019;38(1):389.
   PubMed Web of Science ®Google Scholar
• Hippe A, Braun SA, Oláh P, et al. EGFR/Ras-induced CCL20 production modulates the tumour microenvironment. Br J Cancer. 2020;123(6):942–954.
   PubMed Web of Science ®Google Scholar
• He H, Wu J, Zang M, et al. CCR6(+) B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis. Am J Cancer Res. 2017;7(5):1151–1163.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–257.
   PubMed Web of Science ®Google Scholar
• Jin P, Shin SH, Chun YS, et al. Astrocyte-derived CCL20 reinforces HIF-1-mediated hypoxic responses in glioblastoma by stimulating the CCR6-NF-kappaB signaling pathway. Oncogene. 2018;37(23):3070–3087.
   PubMed Web of Science ®Google Scholar
• Ye L-Y, Chen W, Bai X-L, et al. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 2016;76(4):818.
   PubMed Web of Science ®Google Scholar
• Nicosia RF, Zhu WH, Fogel E, et al. A new ex vivo model to study venous angiogenesis and arterio-venous anastomosis formation. J Vasc Res. 2005;42(2):111–119.
   PubMed Web of Science ®Google Scholar
• Benkheil M, Van Haele M, Roskams T, et al. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): potential role in HCV-related liver cancer. Exp Cell Res. 2018;372(2):168–177.
   PubMed Web of Science ®Google Scholar
• Jayaraman S, Doucet M, Kominsky SL, et al. CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells. Oncol Lett. 2018;15(1):871–878.
   PubMed Web of Science ®Google Scholar
• Bruno A, Pagani A, Pulze L, et al. Orchestration of angiogenesis by immune cells. Front Oncol. 2014;4(131). DOI:10.3389/fonc.2014.00131.
   PubMedGoogle Scholar
• Pastushenko I, Blanpain C. EMT transition States during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–226.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang Y, Qiu Y, et al. Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma. Bioengineered. 2021;12(1):2175–2186.
   PubMed Web of Science ®Google Scholar
• Li T, Zhao N, Lu J, et al. Epigallocatechin gallate (EGCG) suppresses epithelial-mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/smad signaling pathways. Bioengineered. 2019;10(1):282–291.
   PubMed Web of Science ®Google Scholar
• Roche J. The epithelial-to-mesenchymal transition in cancer. Cancers (Basel). 2018;10(2):52.
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016. Cell. 2016;166(1):21–45.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem. 2016;74:103–141.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang X, Shang M, et al. Dysregulated expression of slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J Surg Oncol. 2013;107(2):188–194.
   PubMed Web of Science ®Google Scholar
• Tran DD, Corsa CA, Biswas H, et al. Temporal and spatial cooperation of snail1 and twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res. 2011;9(12):1644–1657.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang W, Lu W, et al. Inhibin β-A (INHBA) induces epithelial–mesenchymal transition and accelerates the motility of breast cancer cells by activating the TGF-β signaling pathway. Bioengineered. 2021;12(1):4681–4696.
   PubMed Web of Science ®Google Scholar
• Wu H-T, Zhong H-T, Li G-W, et al. Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer. J Transl Med. 2020;18(1):51.
   PubMed Web of Science ®Google Scholar
• Cheng X-S, Li Y-F, Tan J, et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial–mesenchymal transition. Cancer Lett. 2014;348(1–2):77–87.
   PubMed Web of Science ®Google Scholar
• Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15(2):201–212.
   PubMed Web of Science ®Google Scholar
• Martins LM, de Melo Escorcio Dourado CS, Campos-Verdes LM, et al. Expression of matrix metalloproteinase 2 and 9 in breast cancer and breast fibroadenoma: a randomized, double-blind study. Oncotarget. 2019;10(64):6879–6884.
   PubMedGoogle Scholar
• Huang H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances. Sensors (Basel). 2018;18(10):3249.
   PubMed Web of Science ®Google Scholar
• Mondal S, Adhikari N, Banerjee S, et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: a minireview. Eur J Med Chem. 2020;194:112260.
   PubMed Web of Science ®Google Scholar
• Lv Y, Zhao X, Zhu L, et al. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis. Theranostics. 2018;8(10):2830–2845.
   PubMed Web of Science ®Google Scholar
• Webb AH, Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017;17(1):434.
   PubMedGoogle Scholar
• Stemmler MP, Eccles RL, Brabletz S, et al. Non-redundant functions of EMT transcription factors. Nat Cell Biol. 2019;21(1):102–112.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V, et al. EMT factors and metabolic pathways in cancer. Front Oncol. 2020;10:499.
   PubMed Web of Science ®Google Scholar
• Gyamfi J, Eom M, Koo J-S, et al. Multifaceted roles of interleukin-6 in adipocyte-breast cancer cell interaction. Transl Oncol. 2018;11(2):275–285.
   PubMed Web of Science ®Google Scholar
• Goossens S, Vandamme N, Van Vlierberghe P, et al. EMT transcription factors in cancer development re-evaluated: beyond EMT and MET. Biochim Biophys Acta Rev Cancer. 2017;1868(2):584–591.
   PubMed Web of Science ®Google Scholar
• Even-Ram S, Yamada KM. Cell migration in 3D matrix. Curr Opin Cell Biol. 2005;17(5):524–532.
   PubMed Web of Science ®Google Scholar
• Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678–689.
   PubMed Web of Science ®Google Scholar
• Samaniego R, Gutiérrez-González A, Gutiérrez-Seijo A, et al. CCL20 expression by tumor-associated macrophages predicts progression of human primary cutaneous melanoma. Cancer Immunol Res. 2018;6(3):267–275.
   PubMed Web of Science ®Google Scholar
• Liu W, Wang W, Wang X, et al. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer Lett. 2020;472:59–69.
   PubMed Web of Science ®Google Scholar
• Kadomoto S, Izumi K, Hiratsuka K, et al. Tumor-associated macrophages induce migration of renal cell carcinoma cells via activation of the CCL20-CCR6 axis. Cancers (Basel). 2020;12(1):89.
   Web of Science ®Google Scholar
• Wang B, Shi L, Sun X, et al. Production of CCL20 from lung cancer cells induces the cell migration and proliferation through PI3K pathway. J Cell Mol Med. 2016;20(5):920–929.
   PubMed Web of Science ®Google Scholar
• Kim KY, Baek A, Park YS, et al. Adipocyte culture medium stimulates invasiveness of MDA-MB-231 cell via CCL20 production. Oncol Rep. 2009;22(6):1497–1504.
   PubMed Web of Science ®Google Scholar
• Lee SK, Park -K-K, Kim H-J, et al. Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis. Sci Rep. 2017;7(1):9610.
   PubMedGoogle Scholar
• Zhong X, Xiu H, Bi Y, et al. Targeting eIF5A2 inhibits prostate carcinogenesis, migration, invasion and metastasis in vitro and in vivo. Bioengineered. 2020;11(1):619–627.
   PubMed Web of Science ®Google Scholar
• Yin D, Lu X. Silencing of long non-coding RNA HCP5 inhibits proliferation, invasion, migration, and promotes apoptosis via regulation of miR-299-3p/SMAD5 axis in gastric cancer cells. Bioengineered. 2021;12(1):225–239.
   PubMed Web of Science ®Google Scholar
• Han G, Wu D, Yang Y, et al. CrkL meditates CCL20/CCR6-induced EMT in gastric cancer. Cytokine. 2015;76(2):163–169.
   PubMed Web of Science ®Google Scholar
• Zeng W, Chang H, Ma M, et al. CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production. Exp Mol Pathol. 2014;97(1):184–190.
   PubMed Web of Science ®Google Scholar
• Chen W, Qin Y, Wang D, et al. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018;16(7):e2005869.
   PubMed Web of Science ®Google Scholar
• Wang D, Yang L, Yu W, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling. J Immunother Cancer. 2019;7(1):215.
   PubMed Web of Science ®Google Scholar
• Fattore L, Sacconi A, Mancini R, et al. MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma. Cytokine Growth Factor Rev. 2017;36:39–48.
   PubMed Web of Science ®Google Scholar
• Dama P, Tang M, Fulton N, et al. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7(1):175.
   PubMedGoogle Scholar
• Wang D, Yang L, Yu W, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling. J Immunother Cancer. 2019;7(1):215.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25(3):94–102.
   PubMed Web of Science ®Google Scholar
• Gales D, Clark C, Manne U, et al. The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol. 2013;2013:859154.
   PubMedGoogle Scholar
• Zhang G, Luo X, Zhang W, et al. CXCL-13 regulates resistance to 5-fluorouracil in colorectal cancer. Cancer Res Treat. 2020;52(2):622–633.
   PubMed Web of Science ®Google Scholar
• Nguyen LV, Vanner R, Dirks P, et al. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12(2):133–143.
   PubMed Web of Science ®Google Scholar
• Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell. 2007;1(4):353–355.
   PubMed Web of Science ®Google Scholar
• Kachalaki S, Ebrahimi M, Mohamed Khosroshahi L, et al. Cancer chemoresistance; biochemical and molecular aspects: a brief overview. Eur J Pharm Sci. 2016;89:20–30.
   PubMed Web of Science ®Google Scholar
• Chen M, Su J, Feng C, et al. Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the notch1 signaling pathway in ovarian cancer. Mol Med Rep. 2021;24(3):635.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang H, Chen X, et al. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2:141–160.
   PubMedGoogle Scholar
• Li T, Quan H, Zhang H, et al. Silencing cyclophilin A improves insulin secretion, reduces cell apoptosis, and alleviates inflammation as well as oxidant stress in high glucose-induced pancreatic β-cells via MAPK/NF-kb signaling pathway. Bioengineered. 2020;11(1):1047–1057.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang L, Joo D, et al. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.
   PubMed Web of Science ®Google Scholar
• Gao W, Gao J, Chen L, et al. Targeting XIST induced apoptosis of human osteosarcoma cells by activation of NF-kB/PUMA signal. Bioengineered. 2019;10(1):261–270.
   PubMed Web of Science ®Google Scholar
• Reedijk M. Notch signaling and breast cancer. Adv Exp Med Biol. 2012;727:241–257.
   PubMed Web of Science ®Google Scholar
• Yao Y, Li X, Cheng L, et al. Circular RNA FAT atypical cadherin 1 (circFAT1)/microRNA-525-5p/spindle and kinetochore-associated complex subunit 1 (SKA1) axis regulates oxaliplatin resistance in breast cancer by activating the notch and Wnt signaling pathway. Bioengineered. 2021;12(1):4032–4043.
   PubMed Web of Science ®Google Scholar
• Obata Y, Kimura S, Nakato G, et al. Epithelial-stromal interaction via notch signaling is essential for the full maturation of gut-associated lymphoid tissues. EMBO Rep. 2014;15(12):1297–1304.
   PubMed Web of Science ®Google Scholar
• Küçükköse C, Ö: YÖ. Effects of notch signalling on the expression of SEMA3C, HMGA2, CXCL14, CXCR7, and CCL20 in breast cancer. Turk J Biol. 2019;43(1):70–76.
   PubMed Web of Science ®Google Scholar
• Kirshberg S, Izhar U, Amir G, et al. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PloS One. 2011;6(9):e24856–e24856.
   PubMed Web of Science ®Google Scholar
• Lauriola L, Serini S, Granone P, et al. Hu/elav RNA-binding protein HuR regulates parathyroid hormone related peptide expression in human lung adenocarcinoma cells. Histol Histopathol. 2013;28(9):1205–1216.
   PubMed Web of Science ®Google Scholar
• Woo HH, Zhou Y, Yi X, et al. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene. 2009;28(9):1176–1186.
   PubMed Web of Science ®Google Scholar
• Jayaraman S, Doucet M, Kominsky SL, et al. Down-regulation of CITED2 attenuates breast tumor growth, vessel formation and TGF-β-induced expression of VEGFA. Oncotarget. 2017;8(4):6169–6178.
   PubMedGoogle Scholar
• Minemura H, Takagi K, Sato A, et al. CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. Cancer Sci. 2016;107(12):1898–1908.
   PubMed Web of Science ®Google Scholar
• Jayaraman S, Doucet M, Lau WM, et al. CITED2 modulates breast cancer metastatic ability through effects on IKKα. Mol Cancer Res. 2016;14(8):730–739.
   PubMed Web of Science ®Google Scholar
• Bakker WJ, Harris IS, Mak TW, et al. FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell. 2007;28(6):941–953.
   PubMed Web of Science ®Google Scholar
• Cruceriu D, Baldasici O, Balacescu O, et al. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol. 2020;43(1):1–18.
   PubMed Web of Science ®Google Scholar
• Iwamoto S, Kido M, Aoki N, et al. TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. Clin Immunol. 2013;146(1):15–25.
   PubMed Web of Science ®Google Scholar